Search

Research

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model.

News & Events

Cancer researchers at The Kids for Child Health Research have developed a new test that can rapidly detect the loss of genes in cancer cells.

News & Events

One of WA’s biggest ever philanthropic gifts will transform childhood cancer research and treatment by improving outcomes for children with cancer and discovering more effective and less toxic treatments.

News & Events

Two outstanding Perth Children’s Hospital clinicians will be supported to pursue a career in medical research, paving the way for more clinician-scientists in Western Australia.

News & Events

Dr Laurence Cheung is doing everything he can to end the threat of childhood leukemia. His research has the potential to change countless lives, but he also has another important job – being a dad to three beautiful children.

News & Events

Three The Kids researchers are collaborating on a cancer research project that has been awarded a $1.75mill grant by the Australian Cancer Research Fund.

News & Events

The Robert Connor Dawes Foundation has joined forces with the Ethan Davies Fellowship to co-fund a The Kids Research Institute Australia initiative aimed at uncovering new treatments for aggressive childhood brain tumours.

News & Events

Kids born with Down syndrome are at high risk of an array of health problems. One of the lesser-known complications is their increased risk of childhood leukaemia.

News & Events

Two The Kids Research Institute Australia researchers have been awarded prestigious grants from the Raine Medical Research Foundation for projects in childhood cancer and newborn infection control.

Research

Standard-risk WNT medulloblastoma patients have an excellent prognosis using the combination of standard dose craniospinal radiotherapy (CSI) followed by platinum and alkylator based chemotherapy. A recent pilot study that attempted to completely omit radiotherapy was terminated early as all patients relapsed rapidly. The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.